Indication · Cardiology
Mitral regurgitation
Last checked: Nov 20, 2026Source: FDA, ClinicalTrials.gov
Devices
136
Cleared or approved since 2000
PMA and De Novo
87
Higher-risk or first-of-kind devices
Breakthrough devices
2
Authorized through June 30, 2026
Recruiting device trials
64
327 device trials in all
Breakthrough-designated devices
- SAPIEN M3 Transcatheter Mitral Valve Replacement SystemEdwards Lifesciences, LLC · 2026
1 more devices with a free account
Devices
136 devices. PMA and De Novo devices first, then devices with the most FDA decisions. Each opens a full summary.
- On-X (R) Prosthetic Heart Valve
On-X Life Technologies, Inc. · PMA · Heart-Valve, Mechanical · newest 2017 · 11 decisions
59 more devices with a free account
Showing the first 60. Narrow by pathway, or open a device type below.
Device trials
Device studies on ClinicalTrials.gov for this condition, any status, newest update first.
Edwards LifesciencesPublic (EW)
NCT03170349 · 124 participants · Start Jun 27, 2017 · Primary completion Jul 30, 2020
Device: Mitral Valve Repair · For: Mitral Valve Regurgitation
Sites: Los Angeles, California; Aurora, Colorado; Evanston, Illinois · 17 sites in all
326 more trials with a free account
Device types
FDA product codes mapped to this indication. The mapping was made with AI help and may include a few loose fits.
- Ring, Annuloplasty (KRH)46
- Replacement Heart-Valve (DYE)26
- Heart-Valve, Non-Allograft Tissue (LWR)26
- Heart-Valve, Mechanical (LWQ)20
- Mitral Valve Repair Devices (NKM)10
- Prosthesis, Mitral Valve, Percutaneously Delivered (NPU)3
- Nonabsorbable Expanded Polytetrafluoroethylene Surgical Suture For Chordae Tendinae Repair Or Replacement (PAW)3
- Catheter, Percutaneous (Valvuloplasty) (MAD)1
- Artificial Chordae Tendineae Surgical Replacement System (SBK)1
Research
- Device studies on mitral regurgitation across PubMed, Europe PMC and OpenAlex
- PubMed ↗
- Google Scholar ↗
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.